Developing as a significant advance in the fight against obesity, the drug is capturing considerable attention . This treatment combines the action of two established GLP-1 binding agonists, dulaglutide , with an new glucose-dependent incretin component. Preliminary study data have shown substantial fat decrease in individuals with excessive we… Read More